Phase III randomized trial of sunitinib malate versus interferon-alfa as first-line systemic therapy for patients with metastatic renal cell carcinoma

被引：0
|
作者：
Rixe, O.
Hutson, T. E.
Tomczak, P.
Michaelson, M. D.
Bukowski, R. M.
Oudard, S.
Negrier, S.
Kim, S. T.
Chen, I.
Figlin, R. A.
Motzer, R. J.
机构：
[1] Univ Paris 06, Hop La Pitie Salpetriere, Paris, France
[2] Baylor Sammons Canc Ctr, Dallas, TX USA
[3] Klin Onkol Oddzial Chemioterapii, Poznan, Poland
[4] Taussig Canc Ctr, Cleveland Clin Fdn, Clemson, SC USA
[5] Hop Europeen Georges Pompidou, Dept Oncol, Paris, France
[6] Ctr Leon Berard, Dept Oncol, F-69373 Lyon, France
[7] Pfizer Global Res & Dev, La Jolla, CA USA
[8] City Hope Comprehens Canc Ctr, Dept Med, Los Angeles, CA USA
[9] Mem Sloan Kettering Canc Ctr, Genitourinary Oncol Serv, New York, NY 10021 USA
来源：
EUROPEAN UROLOGY SUPPLEMENTS | 2007年 / 6卷 / 02期
关键词：
D O I：
10.1016/S1569-9056(07)60855-0
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：237 / 237
页数：1
相关论文
共 50 条
  • [1] Phase III randomized trial of sunitinib malate (SU1 1248) versus interferon-alfa (IFN-α) as first-line systemic therapy for patients with metastatic renal cell carcinoma (mRCC).
    Motzer, R. J.
    Hutson, T. E.
    Tomczak, P.
    Michaelson, M. D.
    Bukowski, R. M.
    Rixe, O.
    Oudard, S.
    Kim, S. T.
    Baum, C. M.
    Figlin, R. A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 2S - 2S
  • [2] Phase III randomized trial of sunitinib malate (SU11248) versus interferon- alfa (IFN-A) as first-line systemic therapy for patients with metastatic renal cell carcinoma (MRCC)
    Motzer, R. J.
    Hutson, T. E.
    Tomczak, P.
    Michaelson, M. D.
    Bukowski, R. M.
    Rixe, O.
    Oudard, S.
    Kim, S. T.
    Baum, C. M.
    Figlin, R. A.
    [J]. ANNALS OF ONCOLOGY, 2006, 17 : 53 - 54
  • [3] Characterizing prior nephrectomy patients with metastatic renal cell carcinoma (mRCC) treated with first-line sunitinib versus interferon-alfa
    Figlin, R. A.
    Hutson, T. E.
    Tomczak, P.
    Michaelson, M. D.
    Bjarnason, G. A.
    Lin, X.
    Lowenthal, S. Pitman
    Korytowsky, B.
    Matczak, E.
    Oudard, S.
    [J]. EUROPEAN JOURNAL OF CANCER, 2013, 49 : S644 - S645
  • [4] Economic evaluations of sunitinib versus interferon-alfa (IFN-α) in first-line metastatic renal cell carcinoma (mRCC)
    Remak, E.
    Mullins, C. D.
    Akobundu, E.
    Charbonneau, C.
    Woodruff, K.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [5] OVERALL SURVIVAL WITH SUNITINIB VERSUS INTERFERON-ALFA (IFN-□) AS FIRST-LINE TREATMENT FOR METASTATIC RENAL CELL CARCINOMA (MRCC)
    Szczylik, C.
    Negrier, S.
    Oudard, S.
    Figlin, R. A.
    Hutson, T. E.
    Tomczak, P.
    Michaelson, M. D.
    Bukowski, R. M.
    Huang, X.
    Kim, S. T.
    Chen, I
    Motzer, R. J.
    [J]. EUROPEAN UROLOGY SUPPLEMENTS, 2009, 8 (04) : 182 - 182
  • [6] Final quality of life (QOL) results with geographical analysis for sunitinib versus interferon-alfa as first-line therapy in patients with metastatic renal cell carcinoma (mRCC)
    Cella, D.
    Michaelson, M. D.
    Bushmakin, A. G.
    Cappelleri, J. C.
    Charbonneau, C.
    Kim, S. T.
    Li, J. Z.
    Motzer, R. J.
    [J]. EJC SUPPLEMENTS, 2009, 7 (02): : 176 - 176
  • [7] Quality of life (QOL) with sunitinib versus interferon-alfa (IFN-α) as first-line therapy in patients with metastatic renal cell carcinoma (mRCC): Final results
    Cella, D.
    Michaelson, M. D.
    Cappelleri, J. C.
    Bushmakin, A. G.
    Charbonneau, C.
    Kim, S. T.
    Li, J. Z.
    Motzer, R. J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [8] FINAL QUALITY OF LIFE (QOL) RESULTS WITH GEOGRAPHICAL ANALYSIS FOR SUNITINIB VERSUS INTERFERON-ALFA, AS FIRST-LINE THERAPY IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA (MRCC)
    Cella, D.
    Michaelson, M. D.
    Bushmakin, A. G.
    Cappelleri, J. C.
    Charbonneau, C.
    Kim, S. T.
    Li, J. Z.
    Motzer, R. J.
    [J]. VALUE IN HEALTH, 2009, 12 (07) : A283 - A283
  • [9] Phase III study of sunitinib malate (SU11248) versus interferon-α as first-line treatment in patients with metastatic renal cell carcinoma
    Reddy, Kesava
    [J]. CLINICAL GENITOURINARY CANCER, 2006, 5 (01) : 23 - 25
  • [10] Cost-Effectiveness Analysis of Sunitinib versus Interferon-Alfa for First-Line Treatment of Advanced and/or Metastatic Renal Cell Carcinoma in Singapore
    Pruis, Sil-ling
    Aziz, Mohamed Ismail Abdul
    Pearce, Fiona
    Tan, Min Han
    Wu, David Bin-Chia
    Ng, Kwong
    [J]. INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE, 2019, 35 (02) : 126 - 133
12345